SG10201404019XA - Muc1 antibodies - Google Patents

Muc1 antibodies

Info

Publication number
SG10201404019XA
SG10201404019XA SG10201404019XA SG10201404019XA SG10201404019XA SG 10201404019X A SG10201404019X A SG 10201404019XA SG 10201404019X A SG10201404019X A SG 10201404019XA SG 10201404019X A SG10201404019X A SG 10201404019XA SG 10201404019X A SG10201404019X A SG 10201404019XA
Authority
SG
Singapore
Prior art keywords
muc1 antibodies
muc1
antibodies
Prior art date
Application number
SG10201404019XA
Inventor
Steffen Goletz
Antje Danielczyk
Renate Stahn
Uwe Karsten
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of SG10201404019XA publication Critical patent/SG10201404019XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201404019XA 2009-07-31 2010-07-30 Muc1 antibodies SG10201404019XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies

Publications (1)

Publication Number Publication Date
SG10201404019XA true SG10201404019XA (en) 2014-09-26

Family

ID=41460131

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201404019XA SG10201404019XA (en) 2009-07-31 2010-07-30 Muc1 antibodies
SG2012000865A SG177527A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012000865A SG177527A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Country Status (17)

Country Link
US (1) US9217038B2 (en)
EP (3) EP2281844A1 (en)
JP (2) JP5922018B2 (en)
KR (1) KR101773506B1 (en)
CN (1) CN102574926B (en)
AR (1) AR077334A1 (en)
AU (1) AU2010278302B2 (en)
BR (1) BR112012002226A2 (en)
CA (1) CA2768888C (en)
CU (1) CU23972B1 (en)
EA (1) EA029954B1 (en)
IL (1) IL217827A (en)
MX (1) MX2012000874A (en)
NZ (1) NZ597563A (en)
SG (2) SG10201404019XA (en)
WO (1) WO2011012309A1 (en)
ZA (1) ZA201200166B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662226C (en) 2006-09-10 2020-08-04 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
EP1920782A1 (en) * 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2603528B1 (en) 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
RU2014110953A (en) 2011-08-22 2015-09-27 Гликотоп Гмбх MICRO-ORGANISMS BEARING TUMOR ANTIGEN
CN103848890B (en) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 The antigenic peptide of MUC1 autoantibody identification
JP6346604B2 (en) 2013-03-01 2018-06-20 学校法人 埼玉医科大学 A method for determining the risk of developing side effects of anticancer drug therapy, comprising detecting a MUC4 gene polymorphism
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3127919A4 (en) * 2014-02-06 2017-08-16 Medicinal Chemistry Pharmaceuticals Co., Ltd. Antibody against mucin 4 (muc 4) glycopeptide and use therefor
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CA2976089A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
CA3043816A1 (en) 2016-11-18 2018-05-24 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
JP7162011B2 (en) * 2017-01-18 2022-10-27 ナノクルーズ・ファーマシューティカル・リミテッド Monoclonal and humanized antibodies against cancer glycopeptides
WO2018138113A1 (en) 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
WO2018178046A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
JP2020515532A (en) 2017-03-29 2020-05-28 グリコトープ ゲーエムベーハー Multispecific antibody constructs that bind to MUC1 and CD3
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
EP3690038A4 (en) 2017-09-29 2021-05-19 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
JP7358367B2 (en) * 2017-10-24 2023-10-10 ジーオー セラピューティクス,インコーポレイテッド Anti-glycoMUC1 antibody and its use
AU2019226387A1 (en) * 2018-03-01 2020-08-20 Glycotope Gmbh Fusion protein constructs comprising an anti-MUC1 antibody and IL-15
CA3100317A1 (en) * 2018-05-17 2019-11-21 Astellas Pharma Inc. Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
KR20210013107A (en) 2018-05-18 2021-02-03 다이이찌 산쿄 가부시키가이샤 Anti-MUC1 antibody-drug conjugate
CN108982854B (en) * 2018-06-19 2021-07-27 哈尔滨医科大学 Application of protein MUC13 in preparation of reagent for diagnosing intrahepatic bile duct cancer
CN112996816A (en) * 2018-06-29 2021-06-18 Go医疗股份有限公司 anti-sugar-MUC 1 antibodies and uses thereof
CN113631229A (en) 2019-03-25 2021-11-09 第一三共株式会社 Antibody-pyrrolobenzodiazepine derivative conjugates
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
AU683413B2 (en) 1992-04-13 1997-11-13 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001012217A1 (en) 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
EP1529060B1 (en) 2002-07-22 2014-09-10 Glycotope GmbH Method for the production of an immunostimulating mucin (muc1)
DK1530628T3 (en) 2002-08-16 2011-01-10 Glycotope Gmbh Process for preparing temperature-induced tumor cell lysates for use as immunogenic compounds
DE10303664A1 (en) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Detection molecules for the treatment and detection of tumors
DK1654353T3 (en) 2003-08-18 2013-08-26 Glycotope Gmbh Tumor Cell Lines NM-F9 (DSM ACC2606) AND NM-D4 (DSM ACC2605) AND APPLICATIONS THEREOF
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
CA2662226C (en) 2006-09-10 2020-08-04 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Also Published As

Publication number Publication date
ZA201200166B (en) 2013-03-27
JP2016041771A (en) 2016-03-31
IL217827A0 (en) 2012-03-29
AR077334A1 (en) 2011-08-17
EA201270207A1 (en) 2012-07-30
JP5922018B2 (en) 2016-05-24
KR20120051724A (en) 2012-05-22
BR112012002226A2 (en) 2016-11-08
CA2768888A1 (en) 2011-02-03
AU2010278302B2 (en) 2014-12-18
KR101773506B1 (en) 2017-08-31
CU20120019A7 (en) 2012-06-21
SG177527A1 (en) 2012-02-28
JP6272916B2 (en) 2018-01-31
US9217038B2 (en) 2015-12-22
IL217827A (en) 2017-05-29
EA029954B1 (en) 2018-06-29
MX2012000874A (en) 2012-02-01
EP2459595A1 (en) 2012-06-06
AU2010278302A1 (en) 2012-02-09
EP2281844A1 (en) 2011-02-09
NZ597563A (en) 2013-08-30
CA2768888C (en) 2019-02-26
US20120128676A1 (en) 2012-05-24
JP2013500703A (en) 2013-01-10
CN102574926A (en) 2012-07-11
WO2011012309A1 (en) 2011-02-03
CN102574926B (en) 2014-10-15
CU23972B1 (en) 2013-12-27
WO2011012309A8 (en) 2011-04-07
EP3421497A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
ZA201200166B (en) Muc1 antibodies
HK1218558A1 (en) Mirac proteins mirac
IL214996A0 (en) Anti-bcma antibodies
IL212175A0 (en) Muc1* antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
HRP20171400T1 (en) Dkk-1 antibodies
ZA201104545B (en) Anti-siglec-15 antibody
EP2427496A4 (en) Anti-vegf-d antibodies
EP2565268A4 (en) Novel muc1 antibody
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
IL240134A0 (en) Novel proteins
EP2499256A4 (en) Anti-c-mpl antibodies
GB2473934B (en) Anti-VEEV antibody
EP2424892A4 (en) Dc-stamp antibodies
GB0908945D0 (en) Antibodies
GB0911712D0 (en) Antibody